Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...
A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from ...
Welcome to Regeneron's conference call to discuss its C5 Complement Development Program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...
The treatment pipeline for generalized myasthenia gravis (gMG) continues to be active, a consequence of the ongoing progress in knowledge that led to approval of six new drugs for the disease. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results